These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 25225800)

  • 21. How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa.
    Larson B; Schnippel K; Ndibongo B; Long L; Fox MP; Rosen S
    PLoS One; 2012; 7(4):e35444. PubMed ID: 22532854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Point-of-care CD4+ technology implementation in Free State, South Africa, was associated with improved patient health outcomes.
    Van Turha L; Maharaj K; Rose A; Boeke C; Peter TF; Vojnov L; Quevedo J; Tsibolane Y
    S Afr Med J; 2020 Jan; 110(2):126-131. PubMed ID: 32657683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.
    Azzoni L; Foulkes AS; Liu Y; Li X; Johnson M; Smith C; Kamarulzaman AB; Montaner J; Mounzer K; Saag M; Cahn P; Cesar C; Krolewiecki A; Sanne I; Montaner LJ
    PLoS Med; 2012; 9(4):e1001207. PubMed ID: 22529752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the cost-effectiveness of point-of-care platforms for infant diagnosis of HIV in sub-Saharan African countries.
    Salvatore PP; de Broucker G; Vojnov L; Moss WJ; Dowdy DW; Sutcliffe CG
    AIDS; 2021 Feb; 35(2):287-297. PubMed ID: 33394672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.
    Luong Nguyen LB; Yazdanpanah Y; Maman D; Wanjala S; Vandenbulcke A; Price J; Parker RA; Hennequin W; Mendiharat P; Freedberg KA
    Clin Infect Dis; 2018 Aug; 67(5):719-726. PubMed ID: 29746619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating implementation and operational costs of an integrated tiered CD4 service including laboratory and point of care testing in a remote health district in South Africa.
    Cassim N; Coetzee LM; Schnippel K; Glencross DK
    PLoS One; 2014; 9(12):e115420. PubMed ID: 25517412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.
    Losina E; Touré H; Uhler LM; Anglaret X; Paltiel AD; Balestre E; Walensky RP; Messou E; Weinstein MC; Dabis F; Freedberg KA; ;
    PLoS Med; 2009 Oct; 6(10):e1000173. PubMed ID: 19859538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern Zambia.
    De Broucker G; Salvatore PP; Mutembo S; Moyo N; Mutanga JN; Thuma PE; Moss WJ; Sutcliffe CG
    PLoS One; 2021; 16(3):e0248217. PubMed ID: 33690733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
    Binagwaho A; Pegurri E; Muita J; Bertozzi S
    PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of point-of-care versus laboratory-based CD4 cell enumeration in HIV-positive pregnant women.
    Myer L; Daskilewicz K; McIntyre J; Bekker LG
    J Int AIDS Soc; 2013 Sep; 16(1):18649. PubMed ID: 24044627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency.
    Francke JA; Penazzato M; Hou T; Abrams EJ; MacLean RL; Myer L; Walensky RP; Leroy V; Weinstein MC; Parker RA; Freedberg KA; Ciaranello A
    J Infect Dis; 2016 Nov; 214(9):1319-1328. PubMed ID: 27540110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.
    Ouattara EN; Ross EL; Yazdanpanah Y; Wong AY; Robine M; Losina E; Moh R; Walensky RP; Danel C; Paltiel AD; Eholié SP; Freedberg KA; Anglaret X
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):294-302. PubMed ID: 24732870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative cost analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South Africa.
    Simeon K; Sharma M; Dorward J; Naidoo J; Dlamini N; Moodley P; Samsunder N; Barnabas RV; Garrett N; Drain PK
    PLoS One; 2019; 14(10):e0223669. PubMed ID: 31618220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact on ART initiation of point-of-care CD4 testing at HIV diagnosis among HIV-positive youth in Khayelitsha, South Africa.
    Patten GE; Wilkinson L; Conradie K; Isaakidis P; Harries AD; Edginton ME; De Azevedo V; van Cutsem G
    J Int AIDS Soc; 2013 Jul; 16(1):18518. PubMed ID: 23830642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.